Organism Attribute

CDC advisors broaden RSV vaccine recommendations to at-risk adults in their 50s

1 week ago talkbio0Tagged 50–59, Adult, Age, Arexvy, broaden, Centers for Disease Control and Prevention (U.S.), Chronic Condition, Recommendation, Respiratory syncytial virus, Severe (severity modifier), Vaccines

Adult, Respiratory syncytial virus, Centers for Disease Control and Prevention (U.S.), Vaccines, Recommendation, Age, Arexvy, Chronic Condition, Severe (severity modifier), 50–59, broaden

Alzheon Investigates Subgroup Data Following Phase 3 Trial of ALZ-801 in Alzheimer’s Disease

2 weeks ago talkbio0Tagged ALZ-801, Alzheimer 's disease, Amyloid-targeting therapy, Apolipoprotein E4, Genotype, Mental deterioration, Mild cognitive disorder, Phase 3 trial, Precision Medicine, Subgroup A Nepoviruses, Valiltramiprosate

Alzheimer’s disease , ALZ-801 , Valiltramiprosate , APOE4 genotype , Mild cognitive impairment (MCI) , Amyloid-targeting therapy , Phase 3 trial results , Cognitive decline , Subgroup analysis , Precision medicine

FDA Rejects Milestone Pharmaceuticals’ Etripamil Nasal Spray for PSVT

4 weeks ago talkbio0Tagged Cardamyst, Complete, etripamil, Milestone, Paroxysmal supraventricular tachycardia, Rejection, Response process, United States Food and Drug Administration

Etripamil, Cardamyst, PSVT, FDA rejection, Complete Response Letter, manufacturing issues, Milestone Pharmaceuticals

Gilead’s Seladelpar Receives Conditional EU Approval for Primary Biliary Cholangitis Treatment

2 months ago talkbio0Tagged Biliary Cholangitis, Commission, Conditional, European (ethnic group), Gilead Sciences, Primary Biliary Cholangitis, Response process, seladelpar, ursodiol

Seladelpar, Gilead Sciences, primary biliary cholangitis, PBC, European Commission, conditional marketing authorization, RESPONSE trial, ursodeoxycholic acid (UDCA)

FDA Approves AbbVie’s Emblaveo for Complicated Intra-Abdominal Infections

2 months ago talkbio0Tagged AbbVie, Antibiotic Resistance, Microbial, avibactam, aztreonam, Emblaveo, Gram-negative bacteria, intra-abdominal infections

Emblaveo, aztreonam, avibactam, antibiotic resistance, Gram-negative bacteria, intra-abdominal infections, AbbVie

RFK Jr. Dodges Vaccine-Autism Questions in Senate Confirmation Responses

3 months ago talkbio0Tagged Autistic Disorder, CHARGE Syndrome, Confirmation, Hearings, Misinformation, Response process, Robert F. Kennedy, Secretary Nomination, Senate, Vaccines, Written - Consent Mode

Robert F. Kennedy Jr., HHS Secretary nomination, vaccine misinformation, autism, Senate confirmation hearings, written responses

CDC Orders Retraction of Research Papers and Removes Website Content Amid New Language Restrictions

3 months ago talkbio0Tagged Centers for Disease Control and Prevention (U.S.), Feeling content, Gender, Languages, LGBTQ+, removal technique, research retraction, restrictions, Scientific Publication, Sense of identity (observable entity), Web Site

CDC, research retraction, website content removal, language restrictions, LGBTQ, gender identity, scientific publications

First Lady Jill Biden Continues to Champion Women’s Health Research Beyond White House Tenure

3 months ago talkbio0Tagged ARPA-H, Gender, Health care facility, health research, Healthcare Disparities, Jill, White House Initiative, women 's

Jill Biden, women’s health research, White House Initiative, ARPA-H, healthcare disparities, gender gap in healthcare

Truveta Genome Project: A Historic 10M Genome Sequencing Initiative Backed by Regeneron, Illumina, and Leading Health Systems

3 months ago talkbio0Tagged Drug Discovery, genetic sequencing, genome sequencing, Genotype, healthcare analytics, Illumina, phenotypic, Precision Medicine, Regeneron, Truveta

Truveta Genome Project, 10M genome sequencing, Regeneron, Illumina, genetic sequencing, genotypic and phenotypic data, healthcare analytics, drug discovery, personalized medicine.

FDA Issues Complete Response Letter for Zealand Pharma’s Glepaglutide in Short Bowel Syndrome Treatment

4 months ago talkbio0Tagged Analog, Complete, Glepaglutide, Glucagon-Like Peptide 2, Rejection, Response process, Short Bowel Syndrome, United States Food and Drug Administration, Zealand Pharma

Zealand Pharma, Glepaglutide, GLP-2 analog, Short Bowel Syndrome (SBS), FDA rejection, Complete Response Letter